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ABSTRACT
Cirmtuzumab may enhance the therapeutic activity of ibrutinib by inhibiting 
ROR1-dependent signaling pathway in patients with chronic lymphocytic leukemia 
(CLL). Mantle cell lymphoma (MCL) is B-cell malignancy that also expresses ROR1. 
In this study, we found that the plasma of patients with MCL had high levels of 
Wnt5a, a ROR1 ligand, that were comparable to those found in patients with CLL; 
in contrast Wnt5a was virtually undetectable in the plasma of age-matched healthy 
adults. We also found that Wnt5a induced Rac1 activation in the primary MCL 
cells. Cirmtuzumab, but not ibrutinib, could inhibit the capacity of Wnt5a to induce 
primary MCL cells to activate Rac1. Addition of exogenous Wnt5a in vitro significantly 
enhanced the numbers of MCL cell divisions and the proportion of dividing MCL 
cells entering S/G2 in MCL cells over time in the presence of CD154 and IL-4/10. 
Treatment of the MCL cells with cirmtuzumab, but not ibrutinib, blocked Wnt5a-
enhanced proliferation of MCL cells. This study indicates that cirmtuzumab and 
ibrutinib may have complementary activity in the treatment of patients with MCL.
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INTRODUCTION
Recent studies have demonstrated that Wnt5a could 
induce activation of Rac1 in leukemia cells of patients with 
CLL via a ROR1-dependent pathway [1], which could not 
be inhibited by ibrutinib [2]. Wnt5a could induce Rac1 
activation to enhance proliferation and survival of ROR1-
expressing CLL cells, even when treated with ibrutinib at 
concentrations that were effective in inhibiting BTK and 
B-cell-receptor (BCR) signaling [2]. Such Wnt5a-induced 
Rac1 activation could be blocked by cirmtuzumab (UC-961), 
a humanized anti-ROR1 mAb, which is undergoing clinical 
evaluation in patients with CLL [3]. Finally, treatment of 
CLL cells with cirmtuzumab and ibrutinib was significantly 
more effective than treatment with either agent alone in 
blocking CLL proliferation and in clearing leukemia cells 
in vivo [2], suggesting that cirmtuzumab may enhance the 
therapeutic activity of ibrutinib in patients with CLL. 
Mantle cell lymphoma (MCL) is B cell malignancy 
that also expresses ROR1 [4]. However, it is not known 
whether Wnt5a can induce Rac1 activation in MCL or 
whether such activation is affected by treatment with 
either ibrutinib or cirmtuzumab. This study demonstrates 
that Wnt5a can induce Rac1 activation, which leads to 
enhanced proliferation of primary MCL cells via a ROR1-
dependent signaling-pathway that can be blocked by 
cirmtuzumab. On the other hand, this signaling-pathway 
cannot be blocked by ibrutinib, even at concentrations that 
completely inhibit BTK or BCR-signaling.
RESULTS
We examined primary neoplastic cells of patients 
with MCL who had circulating leukemia cells for Wnt5a-
induced, ROR1-dependent activation of Rac1. The 
neoplastic B cells of each examined patient (n = 8) each 
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had the t(11;14) cytogenetic abnormality and the immune 
phenotype characteristic of MCL (Supplementary Figure 1). 
We examined for expression of ROR1 by flow 
cytometry and determined the “ROR1 ∆MFI”, which is 
the mean fluorescence intensity of CD19+ cells stained 
with an Alexa-647-conjugated anti-ROR1 mAb (4A5) 
minus the mean fluorescence intensity of the CD19+ cells 
stained with an Alexa-647-conjugated non-specific mAb 
of the same isotype. We found the median ROR1 ∆MFI 
of primary MCL cells was similar with that of CLL cells 
(Figure 1A), which in turn was significantly greater than 
that of healthy-adult blood B cells, which had undetectable 
ROR1 [5]. Similar to what we observed in patients with 
CLL, [1] we also found the plasma of patients with MCL 
have high levels of Wnt5a relative to that of healthy adults 
(Figure 1B). 
MCL cells were cultured with ibrutinib, 
cirmtuzumab, or both ibrutinib and cirmtuzumab for 2 h, 
and then stimulated with exogenous Wnt5a for 30 min. 
Ibrutinib or cirmtuzumab did not induce apoptosis of MCL 
cells under these culture conditions, which did not include 
complement or immune effector cells. For comparison, 
cells from the same MCL sample were cultured without 
Wnt5a in parallel. This revealed that Wnt5a induced Rac1 
activation in the primary MCL cells and that this effect 
could be blocked by cirmtuzumab, but not ibrutinib, as 
observed with primary CLL cells (Figure 1C–1D). 
We induced proliferation of MCL cells by culturing 
MCL cells with recombinant interleukin (IL)-4 and 
IL-10 together with HeLa cells transfected to express 
CD154 (HeLaCD154) [6, 7]. To examine for proliferating 
cells, we stained the MCL cells with carboxyfluorescein 
succinimidyl ester (CFSE), allowing us to monitor for 
cells with lower fluorescence that had undergone cell 
division. Addition of exogenous Wnt5a to co-cultures 
of MCL cells on HeLaCD154 cells significantly enhanced 
the proportion of MCL cells undergoing cell division 
(Figure 2A–2B). Moreover, treatment of the MCL cells 
with cirmtuzumab, but not ibrutinib, blocked the capacity 
of Wnt5a to enhance MCL-cell proliferation (Figure 
2A–2B). Cell-cycle analysis on permeabilized MCL cells 
using propidium iodide showed that Wnt5a stimulation 
significantly enhanced the fraction of CD154-stimulated 
MCL cells in S/G2 (Figure 2C–2D). The capacity of 
Wnt5a to enhance the proportion of cells in S/G2 could be 
inhibited by treatment with cirmtuzumab, but not ibrutinib 
(Figure 2C–2D). Collectively, these data demonstrate that 
cirmtuzumab could block Wnt5a-signaling leading to 
enhanced MCL-cell proliferation, which was not affected 
by treatment with ibrutinib.
DISCUSSION
In this study, we examined primary circulating 
leukemia cells of patients with MCL undergoing treatment 
with ibrutinib, which is highly effective at inhibiting 
BCR-signaling through its capacity to inhibit BTK. 
[8, 9] First, we noted that median ROR1 expression level 
of primary MCL cells was similar with that of CLL cells 
and that the plasma of patients with MCL had high levels 
of Wnt5a that were comparable to those found in patients 
with CLL; in contrast Wnt5a was virtually undetectable in 
the plasma of age-matched healthy adults. We found that 
Wnt5a can induce Rac1 activation in the primary MCL 
cells, as noted in a variety of cell types, [10–12] including 
CLL cells, [1] and cirmtuzumab, but not ibrutinib, could 
inhibit the capacity of Wnt5a to induce primary MCL cells 
to activate Rac1, which is similar to the findings of Ren and 
colleagues, who reported that ibrutinib could not inhibit 
FcγR-induced Rac1 activation, even though it could inhibit 
FcγR-induced calcium signaling and cytokine production, 
[13] and our previous reporting that Wnt5a-signaling was 
dependent upon ROR1, but not ibrutinib, as indicated by 
the capacity of cirmtuzumab to inhibit Wnt5a-induced 
activation of Rac1 in CLL cells [2]. We conclude that 
ibrutinib cannot block ROR1-dependent Wnt5a-induced 
activation of Rac1, which serves as an intracellular signal 
transducer that can influence multiple signaling pathways.
Prior studies found that activated Rac1 could enhance 
resistance of neoplastic cells to cytotoxic drugs. One study 
found that activated T cells and fibroblasts could induce 
activation of Rac1 in neoplastic B cells and thereby enhance 
their resistance to the cytotoxic effects of fludarabine 
monophosphate; inhibition of activated Rac1, on the 
other hand, could enhance the sensitivity of neoplastic B 
cells to the cytotoxic effects of this drug [14]. In another 
study, Rac1 was found to interact with and enhance the 
function of Bcl-2 [15]. which could inhibit spontaneous 
or drug-induced apoptosis. Conversely, another study 
found that treatment of leukemia B cells with NSC-23766, 
an inhibitor of activated Rac1, enhanced the capacity of 
Bcl-2 antagonists to induce apoptosis [16]. Loss of p53 
in lymphoma B cells has been associated with increased 
activation of Rac1, which could be inhibited by NSC-23766 
or a dominant-negative form of Rac1, Rac1N17, causing 
a dose-dependent increase in the rate of spontaneous or 
drug-induced apoptosis [17]. Furthermore, activation 
of Rac1-GTPase can enhance proliferation [1, 2, 14], 
whereas loss of activated Rac1 can result in impaired 
hematopoietic-cell growth [18]. As such, the activated Rac1 
observed in MCL cells may provide an ancillary stimulus, 
which may enhance the survival of MCL cells of patients 
treated with ibrutinib, which typically lacks the ability 
to induce complete responses in most patients treated. 
Conceivably, concomitant treatment of patients with 
MCL using cirmtuzumab and ibrutinib could improve the 
complete response rate to ibrutinib therapy, which yields 
lower overall response rates and a shorter progression free 
survival for patients with MCL than for patients with CLL 
[19–21].
In summary, this study demonstrates that Wnt5a can 
induce ROR1-dependent activation of Rac1 in MCL and 
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that such signaling could be inhibited by cirmtuzumab. 
Because ROR1-signaling induces activation of Rac1 via 
a pathway that cannot be inhibited by ibrutinib, these 
results support the notion that ibrutinib and cirmtuzumab 
may have complementary effects in the treatment of 
patients with MCL. These results are comparable to 
what we observed with CLL B cells, for which we found 
cirmtuzumab to have synergistic and complementary anti-
tumor activity with ibrutinib in clearing leukemia cells in 
3 different animal models [2]. Collectively, these results 
provide rationale for clinical testing of these drugs in 
combination to determine the safety and clinical activity 
of cirmtuzumab and ibrutinib in patients with relapsed or 
refractory CLL or MCL.
MATERIALS AND METHODS
Blood samples
Blood samples were collected from MCL patients 
at the University of California San Diego Moores Cancer 
Center who satisfied diagnostic and immunophenotypic 
criteria for MCL, and who provided written, informed 
consent, in compliance with the Declaration of Helsinki 
and the Institutional Review Board (IRB) of the University 
of California San Diego (IRB approval number 080918). 
PBMCs, of which >90% were MCL cells, were isolated 
as described [1].
Flow cytometry analysis
Flow cytometry analysis was performed as 
described [22]. The following antibodies were used to 
stain cells at 4° C for 20 min: anti-ROR1 mAb (4A5) 
conjugated with Alexa-647 (4A5-Alexa-647) was 
generated in our laboratory. Anti-CD23 mAb conjugated 
with FITC (anti-CD23-FITC) was ordered from Life 
Technologies (Cat #MHCD2301). Anti-CD200 mAb 
conjugated with PE (anti-CD200-PE) was obtained from 
BD Biosciences (Cat #552475). PerCP-Cy5.5 conjugated 
anti-CD19 was purchased from Ebioscience (Cat #45-
0199-42) and PE conjugated anti-CD5 antibodies were 
from BD Biosciences (Cat, #555355). The stained cells 
were washed twice with FACS buffer (phosphate buffered 
saline, pH 7.4 (PBS), 3% FBS), and examined by four-
color, multiparameter flow cytometry using a dual-laser 
FACSCalibur (BD Biosciences), and the data were 
analyzed using FlowJo software (TreeStar). We subtracted 
Figure 1: Cirmtuzumab inhibits Wnt5a-Induced Rac1 activation in ibrutinib-treated MCL cells. (A) DMFI of ROR1 in 
MCL vs CLL (n = 8). The P value was determined by Student’s t test; ns = not significant. (B) Plasma Wnt5a in patients with MCL versus 
age-matched control subjects (n = 4 per group; P < 0.05, Student’s t test). (C) Activated Rac1 was measured in MCL cells, which were 
treated with or without Wnt5a (200 ng/ml), with or without ibrutinib (0.5 µM), or with or without cirmtuzumab (10 μg/ml), as indicated 
above each lane of the immunoblot. The numbers below each lane are the ratios of band integrated optical density (IOD) of activated 
versus total Rac1 normalized to untreated samples (defined as the “IOD of Rac1”). (D) Depicts the mean IOD of Rac1, as defined in 1C, 
in Wnt5a-stimulated MCL cells treated with or without cirmtuzumab and/or ibrutinib observed in three independent experiments (± SEM). 
****P < 0.0001, as calculated using one-way ANOVA with Tukey’s multiple comparisons test.
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the mean-fluorescence intensity (MFI) of cells stained 
with a fluorochrome-labeled, isotype-control mAb from 
the MFI of the same cells stained with each antibody to 
determine the specific increase in MFI (ΔMFI).
Rac1 activation assay
Rac1 activation assay reagents were purchased from 
Cytoskeleton and used as per manufacturer’s instruction. 
Briefly, GTP-bound active Rac1 were pulled down with 
PAK-PBD beads, and then subjected to immunoblot 
analysis. Immunoblots of whole-cell lysates were used to 
assess for total Rac1. The integrated optical density (IOD) 
of bands was evaluated by densitometry and analyzed using 
Gel-Pro Analyzer 4.0 software (Media Cybernetics, MD).
Immunoblot analysis
Western blot analysis was performed as described 
[22]. Equal amounts of total protein from each sample 
were fractionated by SDS-PAGE and blotted onto 
polyvinylidene difluoride membrane. Western blot 
analysis was performed using primary mAb specific for 
Rac1, which were detected using secondary antibodies 
conjugated with horseradish peroxidase (Cell Signaling 
Technology).
Plasma Wnt5a enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) kit 
(MyBioSource) was used to measure Wnt5a levels in 
plasma samples from 9 patients with CLL and 9 healthy 
individuals, as per the manufacturer’s instruction.
Figure 2: Cirmtuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated MCL Cells. (A) CD154-induced 
proliferation of CFSE-labeled MCL cells (n = 3) with or without Wnt5a and treated with cirmtuzumab (10 μg/ml) or ibrutinib (0.5 μM). 
One representative MCL sample is shown with the percent of dividing cells. (B) The bars indicate the mean proportions of MCL cells with 
diminished CFSE fluorescence from each of 3 different patients for each culture condition, as indicated at the bottom. (C) MCL cells (n = 3) 
were cultured with or without Wnt5a in the presence of CD154 and IL-4/10, and then treated with cirmtuzumab (10 μg/ml) or ibrutinib 
(0.5 μM) for 4 days, subjected to cell-cycle analysis following propidium iodide staining. One representative MCL sample is shown. (D) 
The mean fraction of cells in S/G2 phase for all 3 patients tested is presented. Data are shown as mean ± SEM, *P < 0.05, as determined by 
one-way ANOVA with Tukey’s multiple comparisons test.
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Cell proliferation assay
MCL cells were labeled by carboxyfluorescein 
succinimidyl ester (CFSE, Life Technologies) and 
plated at 1.5 × 106/well/ml in a 24-well tray on a layer 
of irradiated HeLaCD154 cells (8000 Rad; 80 Gray) at a 
MCL/HeLaCD154 cell ratio of 15:1 in complete RPMI-
1640 medium supplemented 5 ng/mL of recombinant 
human interleukin (IL)-4 (R&D Systems) and 15 ng/mL 
recombinant human IL-10 (R&D Systems). Wnt5a 
(200 ng/ml, R&D Systems) or cirmtuzumab (10 μg/ml) 
as indicated in the text. CFSE-labeled MCL cells were 
analyzed by flow cytometry; Modfit LT software (version 
3.0, Verity Software House) was used for analysis of cell 
proliferation as previously described44,45.
Cell cycle analyses
MCL cells (1 × 107) were suspended in 100 µl of PBS 
and fixed overnight at 4° C by adding 1 ml cold ethanol. Cells 
were spin at 700 × g for 2 min and washed twice with PBS 
containing 1% BSA. The pelleted cells were then suspended 
in 500 µl of PBS containing 1% BSA and 1 µl of RNase 
(100 mg/ml); RNase was added to digest RNA. PI solution 
(0.5 mg/ml in 38 mM sodium citrate, pH 7.0), 1 µl boiled 
RNase A (100 mg/ml), and PI-staining solution (0.5 mg/ml 
in 38 mM sodium citrate, pH 7.0; 60 µl) were added to cells 
and incubated in the dark for 1 hour at room temperature. 
Immediately thereafter, the cells were analyzed via flow 
cytometry using a FACSArray (Becton Dickinson), and data 
were analyzed using FlowJo software (Tree Star Inc.). 
Statistics
Data are presented as mean ± SEM as indicated, 
for data sets that satisfied conditions for a normal 
distribution, as determined by the Kolmogorov-Smirnov 
test. Differences between two groups were determined 
by unpaired 2-tailed Student’s t test. The statistical 
significance of the difference between means was assessed 
by one-way ANOVA with Tukey’s multiple comparisons 
test. P values less than 0.05 were considered significant. 
Analysis for significance was performed with GraphPad 
Prism 6.0 (GraphPad Software Inc.).
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